MedTrace Logo

Tumor Necrosis Factor Decreases Vitamin D Dependant Calcium Absorption

NCT00427804 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 9

Last updated 2013-02-04

Study results available
· View outcomes & findings →

Summary

This study is a pilot study to determine whether patients with TNFα excess have decreased calcium absorption in response to calcitriol (1,25-dihydroxyvitamin D, the active form of vitamin D) compared to normal controls. This initial pilot study is being done to determine if it is feasible to conduct a study where TNFα could be blocked (e.g., by anti-TNFα therapy such as Enbrel® or Remicade®) to improve vitamin D dependant calcium absorption and thus bone health.

Conditions

Interventions

DRUG

calcitriol

0.25 mcg PO BID for 1 week for low dose then 0.25 mcg PO BID for high dose

Sponsors & Collaborators

  • Emory University

    collaborator OTHER

  • Atlanta VA Medical Center

    lead FED

Principal Investigators

  • Vin Tangpricha, M.D. Ph.D. · Emory University

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2007-01-31
Primary Completion
2009-08-31
Completion
2009-11-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00427804 on ClinicalTrials.gov